Pharma Business review is using cookies

ContinueLearn More
Close
August 17, 2018

Merck, Eisai win FDA approval for Lenvima to treat unresectable HCC

Merck and Eisai have secured approval from the US Food and Drug Administration (FDA) for kinase inhibitor Lenvima (lenvatinib) as the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC).

Image: Eisai head office in Tokyo. Photo: courtesy of Arthena.